Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 181Lymphoma 97Lymphoma, Large B-Cell, Diffuse 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Sarcoma 69Hodgkin Disease 54Lymphoma, Non-Hodgkin 41Triple Negative Breast Neoplasms 37Burkitt Lymphoma 36Lymphoma, Mantle-Cell 32Leukemia 32Lymphoma, Follicular 30Multiple Myeloma 28Carcinoma, Hepatocellular 28Neoplasm Metastasis 23Ovarian Neoplasms 21Neoplasms 21Lymphoma, Large-Cell, Anaplastic 18Osteosarcoma 17Lymphoma, B-Cell 17Prostatic Neoplasms 16Neuroblastoma 15Lymphoma, T-Cell, Peripheral 15Urinary Bladder Neoplasms 14Recurrence 13Lymphoma, Large-Cell, Immunoblastic 13Inflammatory Breast Neoplasms 13Immunoblastic Lymphadenopathy 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Stomach Neoplasms 10

Interventions

Sunitinib 4Cyclophosphamide 4Capecitabine 4Bevacizumab 4pazopanib 3Topotecan 3Paclitaxel 3Docetaxel 3Carboplatin 3temsirolimus 2liposomal doxorubicin 2fludarabine 2Sorafenib 2Panobinostat 2NVP-BKM120 2Lapatinib 2Irinotecan 2Immune Checkpoint Inhibitors 2Gemcitabine 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Bortezomib 2vadimezan 1spartalizumab 1somatostatin receptor 2 1selinexor 1selicrelumab 1perifosine 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Solid Tumors × Doxorubicin × Clear all
NCT01702129 2014-09-09

Anti-EGFR Immunoliposomes in Solid Tumors

University Hospital, Basel, Switzerland

Phase 1 Completed
26 enrolled
Other solid neoplasm

Solid Tumors

NCT00500422 2013-02-13

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Completed
134 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡